US FDA has approved Amantadine extended release capsules for treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. It is the first approved medication by FDA for LID. This article discusses detailed prescription information for Amantadine extended release capsules. Till date, there was no approved drug therapy for LID and Amantadine Immediate-Release (IR) is being widely used for levodopa-induced Parkinson’s dyskinesia.
Amantadine IR was originally approved for influenza, with an additional indication for parkinsonism. However, it has not been extensively studied in well-controlled clinical trials and the durability of its effect has been less. Amantadine Extended Release (ER) provides continuous high plasma concentrations (approximately 1500 ng/mL) throughout the day which cannot be achieved with conventional dosing (100 mg 2 or 3 times daily) with…
